# Bladder and Urothelial Cancer Treatments

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, treatment, and management of bladder cancer, particularly urothelial carcinoma. It covers topics such as chemotherapy, cystectomy, neoadjuvant therapy, molecular characterization, metastatic bladder cancer, guidelines for management, and immunotherapy. The papers provide insights into various aspects of bladder cancer research and clinical practice. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10458 |
| Works | 309 |

## Topic papers all

Showing 15 of 309.

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer](https://scholariq.org/papers/a-randomized-trial-of-bevacizumab-an-anti-vascular-endothelial-growth-factor/)
- [European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines](https://scholariq.org/papers/european-association-of-urology-guidelines-on-muscle-invasive-and-metastatic/)
- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study](https://scholariq.org/papers/prognostic-factors-for-overall-survival-in-patients-with-metastatic-renal-cell/)
- [Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer](https://scholariq.org/papers/nephrectomy-followed-by-interferon-alfa-2b-compared-with-interferon-alfa-2b/)
- [Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer](https://scholariq.org/papers/updated-2016-eau-guidelines-on-muscle-invasive-and-metastatic-bladder-cancer/)
- [Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma](https://scholariq.org/papers/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [Comparison of 1,800 Laparoscopic and Open Partial Nephrectomies for Single Renal Tumors](https://scholariq.org/papers/comparison-of-1-800-laparoscopic-and-open-partial-nephrectomies-for-single-renal/)
- [An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign Score](https://scholariq.org/papers/an-outcome-prediction-model-for-patients-with-clear-cell-renal-cell-carcinoma/)
- [Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer](https://scholariq.org/papers/tumor-evolution-and-drug-response-in-patient-derived-organoid-models-of-bladder/)
- [The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours](https://scholariq.org/papers/the-2022-world-health-organization-classification-of-tumours-of-the-urinary/)
- [Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.](https://scholariq.org/papers/cytidine-methylation-of-regulatory-sequences-near-the-pi-class-glutathione-s/)
- [Matched Comparison of Radical Nephrectomy vs Nephron-Sparing Surgery in Patients With Unilateral Renal Cell Carcinoma and a Normal Contralateral Kidney](https://scholariq.org/papers/matched-comparison-of-radical-nephrectomy-vs-nephron-sparing-surgery-in-patients/)

## Topic primary papers

Showing 15 of 146.

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines](https://scholariq.org/papers/european-association-of-urology-guidelines-on-muscle-invasive-and-metastatic/)
- [Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer](https://scholariq.org/papers/updated-2016-eau-guidelines-on-muscle-invasive-and-metastatic-bladder-cancer/)
- [Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma](https://scholariq.org/papers/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma/)
- [Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer](https://scholariq.org/papers/tumor-evolution-and-drug-response-in-patient-derived-organoid-models-of-bladder/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines](https://scholariq.org/papers/european-association-of-urology-guidelines-on-muscle-invasive-and-metastatic-2/)
- [Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology](https://scholariq.org/papers/bladder-cancer-version-1-2026-nccn-clinical-practice-guidelines-in-oncology/)
- [Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial](https://scholariq.org/papers/comparing-open-radical-cystectomy-and-robot-assisted-laparoscopic-radical/)
- [TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors](https://scholariq.org/papers/trophy-u-01-a-phase-ii-open-label-study-of-sacituzumab-govitecan-in-patients/)
- [Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies](https://scholariq.org/papers/renal-cell-carcinoma-in-relation-to-cigarette-smoking-meta-analysis-of-24/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci](https://scholariq.org/papers/a-multi-stage-genome-wide-association-study-of-bladder-cancer-identifies/)
- [Systematic Review and Cumulative Analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Cystectomy](https://scholariq.org/papers/systematic-review-and-cumulative-analysis-of-perioperative-outcomes-and/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.